Search Results - "Chu, Q S C"

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 by Chu, Q. S.-C., Nielsen, T.O., Alcindor, T., Gupta, A., Endo, M., Goytain, A., Xu, H., Verma, S., Tozer, R., Knowling, M., Bramwell, V.B., Powers, J., Seymour, L.K., Eisenhauer, E.A.

“…Fusion transcription genes/oncoproteins generated from translocation-associated sarcomas modulate gene transcription via histone deacetylase-containing…”
Get full text

Key determinants of energy expenditure in cancer and implications for clinical practice by Purcell, S A, Elliott, S A, Baracos, V E, Chu, Q S C, Prado, C M

“…Great discrepancies exist in the reported prevalence of altered energy metabolism (hypo- or hypermetabolism) in cancer patients, which is likely due to the…”
Get full text

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer by Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K

“…Background: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is…”
Get full text

1460PBiopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience by Chu, Q S-C, Agha, A, Devost, N C, Walton, R, Ghosh, S, Ho, C

Get full text

1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors by Johnson, M L, Patel, M R, Ulahannan, S V, Hansen, A, George, B, Chu, Q S-C, Elgadi, M, Ge, M, Duffy, C, Graeser, R, Khedkar, S, Jones, S F, Burris, H

Get full text

Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience by Chu, Q.S.-C., Agha, A., Devost, N.C., Walton, R., Ghosh, S., Ho, C.

Get full text

Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors by Johnson, M.L., Patel, M.R., Ulahannan, S.V., Hansen, A., George, B., Chu, Q.S.-C., Elgadi, M., Ge, M., Duffy, C., Graeser, R., Khedkar, S., Jones, S.F., Burris, H.

Get full text

Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w) by Weiss, G. R., Mita, A., Garrison, M., Chu, S.-C. Q., Syed, S., Haider, O., Bonate, P., Hammond, L. A., Rowinsky, E. K.

“…Abstract only…”
Get full text

Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w) by Weiss, G. R., Mita, A., Garrison, M., Chu, S.-C. Q., Syed, S., Haider, O., Bonate, P., Hammond, L. A., Rowinsky, E. K.

“…Abstract only…”
Get full text

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors by Schwartz, G., Chu, Q. S.-C., Hammond, L. A., Mita, M., Curtright, J., Versola, M. J., Koch, K., Pandite, L. N., Ho, P. T. C., Rowinsky, E. K.

“…Abstract only…”
Get full text

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors by Schwartz, G., Chu, Q. S.-C., Hammond, L. A., Mita, M., Curtright, J., Versola, M. J., Koch, K., Pandite, L. N., Ho, P. T. C., Rowinsky, E. K.

“…Abstract only…”
Get full text

A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification by Takimoto, C. H., Saif, M. W., Lorusso, P. M., Sweeney, C., Ducharme, M. P., Chu, S.-C. Q., Schwartz, G. H., Danna, M., De Jager, R. L., Rowinsky, E. K.

“…Abstract only…”
Get full text

A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification by Takimoto, C. H., Saif, M. W., Lorusso, P. M., Sweeney, C., Ducharme, M. P., Chu, S.-C. Q., Schwartz, G. H., Danna, M., De Jager, R. L., Rowinsky, E. K.

“…Abstract only…”
Get full text